奥来宁在转移性透明细胞或乳头状肾细胞癌中的研究
一项关于奥来宁治疗转移性透明细胞或乳头状肾细胞癌患者的安全性、耐受性和抗肿瘤疗效的 I/II 期、开放标签、单臂研究
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.
研究概览
详细说明
This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 75 patients and is conducted in 3 parts. The study will consist of 3 parts: Part A - an intra-patient dose escalation part, followed by a dose exposure (Part B), followed by a dose expansion (Part C).
Part A, which is now closed, used an intra patient dose escalation design to evaluate safety across multiple dose levels.
The study is currently in Part B, an exposure based dose escalation phase. Patients may be enrolled into either a 24 hour or a 72 hour exposure cohort. Exposure duration is defined by the timing of hemodialysis, as elimination of orellanine occurs primarily through dialysis initiated after infusion. The starting dose for Part B is 0.38 mg/kg, and the total dose per treatment cycle is limited to 2.5 mg/kg, including any replacement doses. A minimum of three patients will be enrolled in each cohort, and escalation to longer exposure durations occurs only after safety evaluation.
Part C is a planned dose expansion phase to further characterize safety and explore preliminary antitumor activity at the selected dose and exposure level.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Hanjing Xie, Ph.D.
- 电话号码:+46737031615
- 邮箱:hanjing.xie@oncorena.com
研究联系人备份
- 姓名:Oncorena Study General Inquiries
- 邮箱:oncorella1@oncorena.com
学习地点
-
-
-
Villejuif、法国、94805
- 招聘中
- Institut de Cancerologie Gustave-Roussy
-
接触:
- Christophe Massard, M.D., Ph.D
- 电话号码:+33142114211
- 邮箱:Christophe.massard@gustaveroussy.fr
-
首席研究员:
- Christophe Massard, M.D., Ph.D.
-
-
-
-
-
Stockholm、瑞典
- 招聘中
- Karolinska University Hospital
-
首席研究员:
- Jeffrey Yachnin
-
接触:
- Jeffrey Yachnin
- 电话号码:+46812370000
- 邮箱:jeffrey.yachnin@regionstockholm.se
-
-
-
-
California
-
Orange、California、美国、92868
- 招聘中
- University of California Irvine
-
接触:
- Nataliya Mar, M.D.
- 电话号码:714-456-5153
- 邮箱:marn@hs.uci.edu
-
首席研究员:
- Nataliya Mar, M.D.
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford
-
接触:
- Sandhya Srinivas, M.D.
- 电话号码:650-498-6000
- 邮箱:sandysri@stanford.edu
-
首席研究员:
- Sandhya Srinivas, MD
-
San Francisco、California、美国、94158
- 招聘中
- University of California San Francisco
-
接触:
- Arpita Desai, M.D.
- 电话号码:415-476-4616
- 邮箱:arpita.desai@ucsf.edu
-
首席研究员:
- Arpita Desai, M.D.
-
-
Missouri
-
St Louis、Missouri、美国、63130
- 招聘中
- Washington University in St. Louis
-
首席研究员:
- Melissa Reimers, MD
-
接触:
- Melissa Reimers, M.D.
- 电话号码:314-273-3713
- 邮箱:mreimers@wustl.edu
-
-
New York
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Comprehensive
-
首席研究员:
- Saby George, MD
-
接触:
- 电话号码:8313 M.D. 716-845-2300
- 邮箱:Saby.George@roswellpark.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- University of Texas - MD Anderson Cancer Center
-
接触:
- Nizar Tannir, M.D.
- 电话号码:713-563-7265
- 邮箱:ntannir@mdanderson.org
-
首席研究员:
- Nizar Tannir, M.D.
-
-
-
-
-
Lisbon、葡萄牙、1649-035
- 招聘中
- START Lisbon - Hospital de Santa Maria Av
-
接触:
- Andre Mansinho, M.D.
- 电话号码:+351 210 405 907
- 邮箱:andre.mansinho@startlisbon.com
-
首席研究员:
- Andre Mansinho, M.D.
-
-
-
-
-
Lleida、西班牙、25004
- 招聘中
- Clinica Mi Nova Alianca
-
接触:
- Santiago Viteri, M.D., Ph.D.
- 电话号码:+ 34 932287445
- 邮箱:santiago.viteri@pratia.com
-
首席研究员:
- Santiago Viteri, M.D.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
-
Has provided written informed consent.
-
Has a diagnosis of histologically confirmed advanced ccRCC or pRCC. No conventional therapy is available or considered appropriate by the treating physician or is declined by the patient.
-
For patients in the expansion portion of the study only: Measurable disease per RECIST version 1.1 criteria.
-
ECOG performance status of 0 - 2.
-
Age ≥18 years.
-
Life expectancy ≥3 months.
-
Has acceptable haematologic laboratory values defined as:
- Neutrophils ≥1.5 × 10^9/L, without growth factor stimulation within 3 weeks prior to the blood test;
- Platelets ≥100 × 10^9/L;
- Haemoglobin ≥5.6 mmol/L (~90 g/L). Use of erythropoietin or blood transfusions are permitted.
-
Has acceptable liver laboratory values defined as:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for patients with liver metastases
- Total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 × ULN
- For patients diagnosed with Gilbert's syndrome, total bilirubin ≤2 × ULN is acceptable.
-
Must be on chronic hemodialysis (on a consistent regimen for the previous three months, with allowance for intermittent treatments as required for volume overload).
-
The patient's treating nephrologist and oncologist agree that the prospect of loss of remaining renal function resulting from this treatment will not significantly change the patient's future and chronic dialysis treatment.
-
Female patients of child-bearing potential and male patients must agree to use 2 forms of highly effective contraception for the duration of study treatment and after the last dose of orellanine for at least 3 months for males and 6 months for females.
-
For females of child-bearing potential, a negative serum pregnancy test at screening.
-
Patients who are willing and able to comply with travel requirements, scheduled visits, treatment schedule, efficacy assessments, laboratory tests, and other study procedures.
Exclusion criteria:
- Diagnosis of any other malignancy within 2 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, superficial melanoma, or carcinoma in situ of the breast or of the cervix, or low grade (Gleason 7 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration)
- Radiotherapy within 2 weeks before first dose.
- Immuno-oncology therapy (IO) given in the last six (6) months prior to enrolment
- Other systemic anti-cancer therapy within 2 weeks before first dose.
- Has not recovered from AEs due to prior anti-cancer medications to at least grade 1 by CTCAE version 5.0 (except for alopecia and grade 2 neuropathy).
- Has received any other investigational product within 4 weeks before first dose.
- Pregnant or breastfeeding women.
- Uncontrolled medical condition including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, or would, in the opinion of the investigator, place the patient at increased risk.
- QTc interval at baseline of ≥470 msec.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part B - 24-Hour Exposure Cohort
Participants receive orellanine (ONC175) as a 30 minute intravenous infusion once during each 28 day treatment cycle. Hemodialysis is performed the day before the infusion and again approximately 24 hours after the infusion to define the exposure period, as orellanine is eliminated primarily through dialysis. Participants will continue their regular hemodialysis schedule throughout the cycle. |
Orellanine administered intravenously |
|
实验性的:Part B - 72 Hour Exposure Cohort
Participants receive orellanine (ONC175) as a 30 minute intravenous infusion once during each 28 day treatment cycle. In this cohort, hemodialysis is performed on the morning of the infusion, and additional hemodialysis sessions occur on the following days. Replacement doses of orellanine may be administered on the days after the initial infusion, depending on the assigned dose level. Hemodialysis is performed approximately 72 hours after the initial infusion to define the extended exposure period, as orellanine is eliminated primarily through dialysis. |
Orellanine administered intravenously |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
奥来宁的最大耐受剂量
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
|
不良事件和实验室异常按 NCI CTCAE v5.0 分级。
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
|
动脉血压测量值的变化
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
|
脉搏率测量值的变化
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
|
呼吸频率测量的变化
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
|
温度测量值的变化
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
|
体检结果变化
大体时间:完成学习后,大约需要1年
|
完成学习后,大约需要1年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
基于肿瘤反应时间的奥来宁疗效
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
基于最佳总体反应的奥来宁的疗效
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
外推到无穷大的曲线下面积
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
曲线下部分面积
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
剂量比例
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
达到最大血浆浓度的时间
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
最大血浆浓度
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
全身间隙
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
分布容积
大体时间:通过学习完成,约1年。
|
通过学习完成,约1年。
|
|
终末半衰期
大体时间:完成学习大约需要1年。
|
完成学习大约需要1年。
|
合作者和调查者
赞助
出版物和有用的链接
一般刊物
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
- Buvall L, Hedman H, Khramova A, Najar D, Bergwall L, Ebefors K, Sihlbom C, Lundstam S, Herrmann A, Wallentin H, Roos E, Nilsson UA, Johansson M, Tornell J, Haraldsson B, Nystrom J. Orellanine specifically targets renal clear cell carcinoma. Oncotarget. 2017 Jul 25;8(53):91085-91098. doi: 10.18632/oncotarget.19555. eCollection 2017 Oct 31.
- Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global Burden of Urologic Cancers, 1990-2013. Eur Urol. 2017 Mar;71(3):437-446. doi: 10.1016/j.eururo.2016.10.008. Epub 2016 Oct 28.
- Hedman H, Holmdahl J, Molne J, Ebefors K, Haraldsson B, Nystrom J. Long-term clinical outcome for patients poisoned by the fungal nephrotoxin orellanine. BMC Nephrol. 2017 Apr 3;18(1):121. doi: 10.1186/s12882-017-0533-6.
- Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Curr Oncol Rep. 2017 Apr;19(4):27. doi: 10.1007/s11912-017-0583-8.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- ONC001-CL-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pursuant to relevant data protection and privacy legislation, patients will authorize the collection, use and disclosure of their study data by the investigator and by those persons who need that information for the purposes of the study.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.